CR20150196A - Moléculas de unión il-17a novedosas y usos médicos de las mismas - Google Patents
Moléculas de unión il-17a novedosas y usos médicos de las mismasInfo
- Publication number
- CR20150196A CR20150196A CR20150196A CR20150196A CR20150196A CR 20150196 A CR20150196 A CR 20150196A CR 20150196 A CR20150196 A CR 20150196A CR 20150196 A CR20150196 A CR 20150196A CR 20150196 A CR20150196 A CR 20150196A
- Authority
- CR
- Costa Rica
- Prior art keywords
- amino acid
- novedous
- ill
- same
- medical uses
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
- C07K14/4703—Inhibitors; Suppressors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/241—Tumor Necrosis Factors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2318/00—Antibody mimetics or scaffolds
- C07K2318/20—Antigen-binding scaffold molecules wherein the scaffold is not an immunoglobulin variable region or antibody mimetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Diabetes (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Epidemiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Pulmonology (AREA)
- Hematology (AREA)
- Toxicology (AREA)
- Marine Sciences & Fisheries (AREA)
- Urology & Nephrology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Obesity (AREA)
- Neurology (AREA)
- Dermatology (AREA)
- Emergency Medicine (AREA)
- Neurosurgery (AREA)
Abstract
La presente invención se relaciona a un polipéptido que inhibe la actividad de IL-17A glicosilada, en donde el polipéptido comprende o consiste de una secuencia de aminoácido seleccionada del grupo que consiste de: (a) GVTLFVALYDY(X1)(X2)(X3)(X4)(X5)(X6)DLSFHKGEKFQILSTHEYEDWWEARSLTTGETGYIPSNYVAPVDSIQ (SEC ID NO: 1), en donde las posiciones de aminoácidos (X1) a (X6) puede ser cualquier secuencia de aminoácido; y (b) una secuencia de aminoácido la cual es al menos 85% idéntica a la secuencia de aminoácido de (a), en donde la determinación de identidad excluye posiciones de aminoácido (X1) a (X6) y siempre que se conserve la secuencia de aminoácido STHEYE (SEC ID NO: 2) en posiciones de aminoácido 31 a 36 de la SEC ID NO: 1.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP20120185425 EP2711016A1 (en) | 2012-09-21 | 2012-09-21 | Novel IL-17A binding molecules and medical uses thereof |
PCT/EP2013/069481 WO2014044758A1 (en) | 2012-09-21 | 2013-09-19 | Novel il-17a binding molecules and medical uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
CR20150196A true CR20150196A (es) | 2015-05-18 |
Family
ID=47010256
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CR20150196A CR20150196A (es) | 2012-09-21 | 2015-04-16 | Moléculas de unión il-17a novedosas y usos médicos de las mismas |
Country Status (17)
Country | Link |
---|---|
US (1) | US9315557B2 (es) |
EP (2) | EP2711016A1 (es) |
JP (1) | JP6009678B2 (es) |
KR (1) | KR20150065677A (es) |
CN (1) | CN104684571B (es) |
AU (1) | AU2013320251B2 (es) |
CA (1) | CA2884290C (es) |
CL (1) | CL2015000709A1 (es) |
CR (1) | CR20150196A (es) |
EA (1) | EA031683B1 (es) |
ES (1) | ES2583832T3 (es) |
IL (1) | IL237845A0 (es) |
MX (1) | MX2015003310A (es) |
PE (1) | PE20150923A1 (es) |
PH (1) | PH12015500461A1 (es) |
SG (1) | SG11201502167WA (es) |
WO (1) | WO2014044758A1 (es) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MX2016010729A (es) | 2014-02-21 | 2016-10-26 | Genentech Inc | Anticuerpos biespecificos anti-il-13 / il-17 y sus usos. |
RU2732226C2 (ru) * | 2014-03-17 | 2020-09-14 | Мицубиси Танабе Фарма Корпорейшн | Конъюгаты антитело-финомер |
JP6943764B2 (ja) | 2015-01-12 | 2021-10-06 | アフィボディ アクティエボラーグ | Il−17a結合ポリペプチド |
WO2016118921A1 (en) * | 2015-01-24 | 2016-07-28 | Abbvie, Inc. | Compositions and methods for treating psoriatic arthritis |
JP2017057201A (ja) * | 2015-09-16 | 2017-03-23 | 田辺三菱製薬株式会社 | 抗体−フィノマー複合体を含む医薬組成物 |
US11072651B2 (en) * | 2016-09-14 | 2021-07-27 | Beijing Hanmi Pharm. Co., Ltd. | Antibody specifically binding to IL-17A, encoding nucleic acid, and method of using the antibody |
CN106769349B (zh) * | 2017-01-06 | 2020-01-21 | 上海君联医疗设备有限公司 | 血液中异常糖基化蛋白细胞的检测方法 |
US10722589B2 (en) | 2017-04-03 | 2020-07-28 | Covagen Ag | FGFR3 binding molecules |
CN107522783B (zh) * | 2017-09-30 | 2020-07-07 | 华博生物医药技术(上海)有限公司 | 一种抗白介素17a的抗体、其制备方法和应用 |
US20190100587A1 (en) | 2017-10-02 | 2019-04-04 | Covagen Ag | IgG1 Fc MUTANTS WITH ABLATED EFFECTOR FUNCTIONS |
US20190153096A1 (en) | 2017-10-02 | 2019-05-23 | Covagen Ag | Cd3/cd33 bispecific binding molecules |
JP2022523908A (ja) | 2019-01-31 | 2022-04-27 | ヌマブ セラピューティクス アクチェンゲゼルシャフト | TNFα及びIL-17Aに対する特異性を有する多重特異性抗体、IL-17Aを標的とする抗体、及びそれらの使用方法 |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
WO1989009622A1 (en) | 1988-04-15 | 1989-10-19 | Protein Design Labs, Inc. | Il-2 receptor-specific chimeric antibodies |
IL162181A (en) | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
EP1690935A3 (en) | 1990-01-12 | 2008-07-30 | Abgenix, Inc. | Generation of xenogeneic antibodies |
WO1994002602A1 (en) | 1992-07-24 | 1994-02-03 | Cell Genesys, Inc. | Generation of xenogeneic antibodies |
DE69637481T2 (de) | 1995-04-27 | 2009-04-09 | Amgen Fremont Inc. | Aus immunisierten Xenomäusen stammende menschliche Antikörper gegen IL-8 |
AU2466895A (en) | 1995-04-28 | 1996-11-18 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
EP1892248A1 (en) | 2006-08-21 | 2008-02-27 | Eidgenössische Technische Hochschule Zürich | Specific and high affinity binding proteins comprising modified SH3 domains of FYN kinase |
JPWO2009107785A1 (ja) * | 2008-02-28 | 2011-07-07 | シスメックス株式会社 | Il−17産生ヘルパーt細胞検出用マーカー及びil−17産生ヘルパーt細胞の検出方法 |
PE20160651A1 (es) | 2009-03-05 | 2016-07-24 | Abbvie Inc | Proteinas de union a il-17 |
NZ598351A (en) | 2009-08-27 | 2014-08-29 | Covagen Ag | Il-17 binding compounds and medical uses thereof |
EP2524927A1 (en) * | 2011-05-20 | 2012-11-21 | Covagen AG | New chymase binding compounds and medical uses thereof |
-
2012
- 2012-09-21 EP EP20120185425 patent/EP2711016A1/en not_active Withdrawn
-
2013
- 2013-09-19 CN CN201380049327.1A patent/CN104684571B/zh active Active
- 2013-09-19 EP EP13766014.8A patent/EP2872163B1/en active Active
- 2013-09-19 KR KR1020157007155A patent/KR20150065677A/ko not_active Application Discontinuation
- 2013-09-19 MX MX2015003310A patent/MX2015003310A/es unknown
- 2013-09-19 CA CA2884290A patent/CA2884290C/en active Active
- 2013-09-19 PE PE2015000393A patent/PE20150923A1/es not_active Application Discontinuation
- 2013-09-19 AU AU2013320251A patent/AU2013320251B2/en not_active Ceased
- 2013-09-19 SG SG11201502167WA patent/SG11201502167WA/en unknown
- 2013-09-19 WO PCT/EP2013/069481 patent/WO2014044758A1/en active Application Filing
- 2013-09-19 ES ES13766014.8T patent/ES2583832T3/es active Active
- 2013-09-19 EA EA201590611A patent/EA031683B1/ru not_active IP Right Cessation
- 2013-09-19 JP JP2015532409A patent/JP6009678B2/ja active Active
- 2013-09-19 US US14/428,245 patent/US9315557B2/en active Active
-
2015
- 2015-03-03 PH PH12015500461A patent/PH12015500461A1/en unknown
- 2015-03-19 IL IL237845A patent/IL237845A0/en unknown
- 2015-03-20 CL CL2015000709A patent/CL2015000709A1/es unknown
- 2015-04-16 CR CR20150196A patent/CR20150196A/es not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
JP2015531604A (ja) | 2015-11-05 |
EA201590611A1 (ru) | 2015-07-30 |
PE20150923A1 (es) | 2015-06-27 |
SG11201502167WA (en) | 2015-04-29 |
AU2013320251B2 (en) | 2017-09-14 |
CL2015000709A1 (es) | 2015-07-31 |
CN104684571B (zh) | 2017-09-22 |
EP2872163A1 (en) | 2015-05-20 |
ES2583832T3 (es) | 2016-09-22 |
EP2872163B1 (en) | 2016-05-04 |
CA2884290A1 (en) | 2014-03-27 |
CN104684571A (zh) | 2015-06-03 |
KR20150065677A (ko) | 2015-06-15 |
CA2884290C (en) | 2021-08-10 |
JP6009678B2 (ja) | 2016-10-19 |
AU2013320251A1 (en) | 2015-03-26 |
WO2014044758A1 (en) | 2014-03-27 |
US9315557B2 (en) | 2016-04-19 |
IL237845A0 (en) | 2015-05-31 |
EA031683B1 (ru) | 2019-02-28 |
PH12015500461A1 (en) | 2015-04-20 |
MX2015003310A (es) | 2016-01-20 |
US20150322125A1 (en) | 2015-11-12 |
EP2711016A1 (en) | 2014-03-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CR20150196A (es) | Moléculas de unión il-17a novedosas y usos médicos de las mismas | |
ES2691070T3 (es) | Péptidos antiinflamatorios y composición que comprende los mismos | |
MX2021006856A (es) | Uso de un peptido para modular la homeostasis de los acidos biliares o tratamiento de una enfermedad relacionada con los acidos biliares. | |
EA201400836A8 (ru) | Получение дитерпена | |
BR112013028407A2 (pt) | "sequências de aminoácido direcionadas em relação aos polipeptídeos de il-17a, il-17f e/ou il17-a/f compreendendo as mesmas, seus usos, polipeptídeos, e composição farmacêutica". | |
MX352205B (es) | Sistemas de expresion. | |
BR112016027871A2 (pt) | composição para melhorar a memória, a função de aprendizado e/ou função cognitiva | |
ES2694667T3 (es) | Método para producir oxalato oxidasas que tienen actividad óptica cerca de pH fisiológico y uso de tales oxalato oxidasas recombinantes en el tratamiento de enfermedades relacionadas con oxalato | |
PE20140617A1 (es) | Alfa glucosidasa acida modificada con procesamiento acelerado | |
WO2014202622A3 (en) | Rasamsonia gene and use thereof | |
PH12016500101A1 (en) | Protease-resistant peptide ligands | |
PE20170955A1 (es) | Nuevas proteinas inhibidoras de insectos | |
EA201300056A1 (ru) | Полипептид с активностью ацетилксиланэстеразы и его применения | |
BR112014030440A8 (pt) | método para preparar um alqueno monoinsaturado | |
PH12017502323A1 (en) | Novel xylanase | |
AR119056A2 (es) | Péptido de fusión, polinucleótido que lo codifica, vector y célula transformada | |
BR112014028130A2 (pt) | Sal de cloridrato de um peptídeo, composição farmacêutica, uso de um sal de cloridrato, uso de uma composição farmacêutica, e, método para evitar ou tratar alergia a gatos | |
NZ709120A (en) | Beta-hexosyl-transferases and uses thereof | |
ES2536238T3 (es) | Péptidos antimicrobianos | |
BR112012033396A2 (pt) | Polipetídeo tendo atividade swollenin e seus usos. | |
BR112016005899A8 (pt) | composições compreendendo populações heterogêneas de proteínas de fator xa de coagulação recombinante humano, seus usos e método de purificação de uma proteína variante de fator xa. | |
NZ738982A (en) | Composition comprising amino acid and cyclic dipeptide | |
CN106687579A8 (zh) | 产生二胺的微生物和使用该微生物产生二胺的方法 | |
MY171183A (en) | Polypeptide glycosylated with sialylated sugar chain | |
AR107725A1 (es) | Composiciones, organismos, sistemas y métodos de cítricos resistentes a patógenos |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Abandonment or withdrawal (granting procedure) |